Navigation Links
Patent Attorney John Rizvi Speaks at FIME International Medical Expo
Date:8/5/2009

The FIME 2009 International Medical Expo is the largest and most comprehensive medical exposition of its kind. John Rizvi will deliver a presentation titled, "Preservation of Legal Rights in Medical Innovations" at the FIME 2009 International Medical Expo in Miami Beach.

Miami, FL (PRWEB) August 5, 2009 -- On August 13, 2009 at 1:00 PM, attorney John Rizvi will deliver a presentation titled, "Preservation of Legal Rights in Medical Innovations" at the FIME 2009 International Medical Expo in Miami Beach.

Florida has one of the country's largest medical device sectors. Florida ranks second in the U.S. for number of FDA-registered medical device establishments, according to the FDA (2007). Over 20,000 Floridians work in this sector.

The FIME 2009 International Medical Expo is the largest and most comprehensive medical exposition of its kind. The exposition will feature medical manufacturers from around the world. It is held at the Miami Beach Convention Center, with over 500,000 square feet of exhibitor space. The four types of featured attendees are medical equipment, medical products, medical services and medical technology companies.

South Florida has seen steady growth in the medical device industry over the past ten years and John Rizvi, a patent attorney who specializes in patenting medical devices, is giving a presentation to educate medical technology companies on the importance of patenting new inventions.

"Patents help eliminate competition by giving patent holders the right to prevent anyone else from making, using, selling, or importing competing products in their market. This allows a patent holder to maintain monopoly pricing and avoids the product becoming a commodity," said Rizvi.

Patents for medical device companies have become increasingly important as more competitors from overseas and nationally are launching knock-off products based on a patent holder's intellectual property.

John Rizvi said that he often sees companies work with attorneys who don't fully understand the medical patent industry and draft claims that are too narrow in scope. This can allow a competitor to "design around" a patented product.

John Rizvi has over 14 years of experience focused exclusively on the preparation and prosecution of U.S. and international patent and trademark applications, patent and trademark validity and infringement opinions, licensing, transactional support, and all aspects of intellectual property litigation. John is an Adjunct Professor at the Nova Southeastern University Shepard Board Law Center where he teaches courses in intellectual property law.

###

Read the full story at http://www.prweb.com/releases/medical/expo/prweb2712834.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. Pressure BioSciences, Inc. Issued First Patent in Canada
4. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
5. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
6. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
7. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
8. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
9. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
10. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
11. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on ... of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ... is expected to deliver therapeutic levels of olanzapine for a period of 3 months., ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing ... financial results for the third quarter and first nine ... Third Quarter of Fiscal 2017 Highlights ... 2017 increased by 18.6% to RMB200.9 million ($28.9 million). ...
Breaking Biology Technology:
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
Breaking Biology News(10 mins):